Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Caldarelli

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Oncotarget|October 18, 2016
Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsAdriana Borriello, Ilaria Caldarelli, Debora Bencivenga, et al.
Cancer Treatment and Research|October 12, 2013
Resveratrol: from basic studies to bedsideAdriana Borriello, Debora Bencivenga, Ilaria Caldarelli, et al.
International Journal of Molecular Sciences|April 5, 2018
Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human DiseasesEmanuela Stampone, Ilaria Caldarelli, Alberto Zullo, et al.
Cancer Letters|July 9, 2017
p27<sup>Kip1</sup> and human cancers: A reappraisal of a still enigmatic proteinDebora Bencivenga, Ilaria Caldarelli, Emanuela Stampone, et al.
American Journal of Hematology|August 6, 2013
Transferrin-immune complex disease: a potentially overlooked gammopathy mediated by IgM and IgGGian Luca Forni, Valeria Pinto, Marco Musso, et al.
Plos One|December 14, 2011
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cellsAdriana Borriello, Ilaria Caldarelli, Maria Assunta Basile, et al.
Cell Cycle (Georgetown, Tex.)|December 9, 2014
P27Kip1 serine 10 phosphorylation determines its metabolism and interaction with cyclin-dependent kinasesDebora Bencivenga, Annunziata Tramontano, Alessia Borgia, et al.
Molecular Cancer Research : MCR|August 6, 2011
p57(Kip2) and cancer: time for a critical appraisalAdriana Borriello, Ilaria Caldarelli, Debora Bencivenga, et al.
Current Pharmaceutical Design|February 12, 2013
Resveratrol and cancer treatment: is hormesis a yet unsolved matter?Adriana Borriello, Debora Bencivenga, Ilaria Caldarelli, et al.
Carcinogenesis|October 19, 2010
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cellsAdriana Borriello, Ilaria Caldarelli, Debora Bencivenga, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Oncotarget|October 18, 2016
Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsAdriana Borriello, Ilaria Caldarelli, Debora Bencivenga, et al.
Cancer Treatment and Research|October 12, 2013
Resveratrol: from basic studies to bedsideAdriana Borriello, Debora Bencivenga, Ilaria Caldarelli, et al.
International Journal of Molecular Sciences|April 5, 2018
Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human DiseasesEmanuela Stampone, Ilaria Caldarelli, Alberto Zullo, et al.
Cancer Letters|July 9, 2017
p27<sup>Kip1</sup> and human cancers: A reappraisal of a still enigmatic proteinDebora Bencivenga, Ilaria Caldarelli, Emanuela Stampone, et al.
American Journal of Hematology|August 6, 2013
Transferrin-immune complex disease: a potentially overlooked gammopathy mediated by IgM and IgGGian Luca Forni, Valeria Pinto, Marco Musso, et al.
Plos One|December 14, 2011
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cellsAdriana Borriello, Ilaria Caldarelli, Maria Assunta Basile, et al.
Cell Cycle (Georgetown, Tex.)|December 9, 2014
P27Kip1 serine 10 phosphorylation determines its metabolism and interaction with cyclin-dependent kinasesDebora Bencivenga, Annunziata Tramontano, Alessia Borgia, et al.
Molecular Cancer Research : MCR|August 6, 2011
p57(Kip2) and cancer: time for a critical appraisalAdriana Borriello, Ilaria Caldarelli, Debora Bencivenga, et al.
Current Pharmaceutical Design|February 12, 2013
Resveratrol and cancer treatment: is hormesis a yet unsolved matter?Adriana Borriello, Debora Bencivenga, Ilaria Caldarelli, et al.
Carcinogenesis|October 19, 2010
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cellsAdriana Borriello, Ilaria Caldarelli, Debora Bencivenga, et al.
Pageof 2